Search Results - "KAHATT, C"

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study by Calvo, E., Moreno, V., Flynn, M., Holgado, E., Olmedo, M.E., Lopez Criado, M.P., Kahatt, C., Lopez-Vilariño, J.A., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Soto Matos-Pita, A., Forster, M.

“…Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the…”
Get full text

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer by Poveda, A., del Campo, J.M., Ray-Coquard, I., Alexandre, J., Provansal, M., Guerra Alía, E.M., Casado, A., Gonzalez-Martin, A., Fernández, C., Rodriguez, I., Soto, A., Kahatt, C., Fernández Teruel, C., Galmarini, C.M., Pérez de la Haza, A., Bohan, P., Berton-Rigaud, D.

“…PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed…”
Get full text

Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients by YOVINE, A, RIOFRIO, M, CVITKOVIC, E, MISSET, J. L, BLAY, J. Y, BRAIN, E, ALEXANDRE, J, KAHATT, C, TAAMMA, A, JIMENO, J, MARTIN, C, SALHI, Y

“…A multicenter phase II study evaluating efficacy, safety, and pharmacokinetics of ecteinascidin-743 (ET-743) in pretreated advanced soft tissue sarcoma…”
Get full text

Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study by Delaloge, S., Wolp-Diniz, R., Byrski, T., Blum, J.L., Gonçalves, A., Campone, M., Lardelli, P., Kahatt, C., Nieto, A., Cullell-Young, M., Lubinski, J.

“…Breast cancer is a heterogeneous disease defined by both germline and somatic abnormalities. In preclinical models, tumors carrying homologous recombination…”
Get full text

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma by Plummer, R, Lorigan, P, Brown, E, Zaucha, R, Moiseyenko, V, Demidov, L, Soriano, V, Chmielowska, E, Andrés, R, Kudryavtseva, G, Kahatt, C, Szyldergemajn, S, Extremera, S, de Miguel, B, Cullell-Young, M, Calvert, H

“…Background: This phase I–II trial compared plitidepsin 1-h infusion alone or combined with dacarbazine (DTIC) 1-h infusion as front-line therapy for advanced…”
Get full text

Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial by Gaillard, S., Oaknin, A., Ray-Coquard, I.L., Vergote, I.B., Scambia, G., Colombo, N., Ghamande, S.A., Soto-Matos, A., Fernandez, C.M., Kahatt, C., Gomez, J., Nieto, A., Torres, N., Pardo-Burdalo, B., Papai, Z., Kristeleit, R.S., O’Malley, D.M., Benjamin, I., Pautier, P., Lorusso, D.

Get full text

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer by Awada, A.H., Boni, V., Moreno, V., Aftimos, P., Kahatt, C., Luepke-Estefan, X.E., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Tabernero, J.

“…Preclinical studies showed a synergistic effect for 5-fluorouracil and lurbinectedin against solid tumors. This phase I trial evaluated a combination of…”
Get full text

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study by Boni, V., Pistilli, B., Braña, I., Shapiro, G.I., Trigo, J., Moreno, V., Castellano, D., Fernández, C., Kahatt, C., Alfaro, V., Siguero, M., Zeaiter, A., Longo, F., Zaman, K., Antón, A., Paredes, A., Huidobro, G., Subbiah, V.

“…Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient…”
Get full text

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors by Capdevila, J., Clive, S., Casado, E., Michie, C., Piera, A., Sicart, E., Carreras, M. J., Coronado, C., Kahatt, C., Soto Matos-Pita, A., Fernandez Teruel, C., Siguero, M., Cullell-Young, M., Tabernero, J.

“…Purpose PM00104 (Zalypsis ® ) is a synthetic tetrahydroisoquinoline alkaloid with potent antiproliferative activity against tumor cell lines. This phase I…”
Get full text

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer by Michaelson, M.D., Bellmunt, J., Hudes, G.R., Goel, S., Lee, R.J., Kantoff, P.W., Stein, C.A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., Lewis, N.L., Smith, M.R.

“…This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration-resistant prostate cancer (CRPC). Two schedules were…”
Get full text

679P Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor by Moreno, I., Hernandez, T., Calvo, E., Fudio, S., Kahatt, C., Martinez, S., Iglesias, J., Calafati, R.O., Pérez Ramos, L., Montilla, L., Zeaiter, A., Lubomirov, R.

Get full text

432 Phase Ib study of plitidepsin with bevacizumab in refractory solid tumor patients (pts) by Gomez-Roca, C, Besse-Hammer, T, Szyldergemajn, S, Bahleda, R, Diaz, M, Vandermeeren, A, Extremera, S, Kahatt, C, Soria, J.C, Awada, A

Get full text

671P Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors by Goel, S., Provencio Pulla, M., De Miguel Luken, M.J., Ghalib, M., Calvo de Juan, V., Hammami, M.B., Vikash, S., Maitra, R., Chaudhary, I., Martinez, S., Kahatt, C., Extremera, S., Fudio, S., Zeaiter, A.

Get full text

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study by Berthon, Céline, MD, Raffoux, Emmanuel, MD, Thomas, Xavier, MD, Vey, Norbert, Prof, Gomez-Roca, Carlos, MD, Yee, Karen, MD, Taussig, David Christopher, MD, Rezai, Keyvan, PhD, Roumier, Christophe, PharmD, Herait, Patrice, MD, Kahatt, Carmen, MD, Quesnel, Bruno, Prof, Michallet, Mauricette, Prof, Recher, Christian, Prof, Lokiec, François, ScD, Preudhomme, Claude, Prof, Dombret, Hervé, Prof

“…Summary Background Bromodomain and extraterminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with…”
Get full text

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study by Amorim, Sandy, MD, Stathis, Anastasios, MD, Gleeson, Mary, FRCPath, Iyengar, Sunil, MD, Magarotto, Valeria, MD, Leleu, Xavier, Prof, Morschhauser, Franck, Prof, Karlin, Lionel, MD, Broussais, Florence, MD, Rezai, Keyvan, ScD, Herait, Patrice, MD, Kahatt, Carmen, MD, Lokiec, François, PhD, Salles, Gilles, Prof, Facon, Thierry, Prof, Palumbo, Antonio, Prof, Cunningham, David, Prof, Zucca, Emanuele, MD, Thieblemont, Catherine, Prof

“…Summary Background The first-in-class small molecule inhibitor OTX015 (MK-8628) specifically binds to bromodomain motifs BRD2, BRD3, and BRD4 of bromodomain…”
Get full text

551P Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final results by Takahashi, S., Shimizu, T., Doi, T., Lopez-Vilarino, J.A., Martin, R. Nunez, Kahatt, C., Teruel, C. Fernandez, Sasamoto, H., Zeaiter, A.

Get full text

A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report by Gomez, H, Kahatt, C, Falcon, S, Santillana, S, de Mendoza, F H, Valdivia, S, Vallejos, C, Otero, J, Pen, D L

“…The purpose of this ongoing study is to determine the response and safety of a combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN)…”
Get more information

471PLurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours by Aix, S Ponce, Flor, M J, Falcón, A, Simón, I Sánchez, Jimenez, E, Coté, G, Nuñez, R, Siguero, M, Insa, M, Cullell-Young, M, Kahatt, C, Zeaiter, A, Paz-Ares, L

“…Abstract Background LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor…”
Get full text

471P - Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours by Aix, S Ponce, Flor, M.J., Falcón, A., Simón, I Sánchez, Jimenez, E., Coté, G., Nuñez, R., Siguero, M., Insa, M., Cullell-Young, M., Kahatt, C., Zeaiter, A., Paz-Ares, L.

“…LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical…”
Get full text

Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours by Aix, S Ponce, Flor, M.J., Falcón, A., Simón, I Sánchez, Jimenez, E., Coté, G., Nuñez, R., Siguero, M., Insa, M., Cullell-Young, M., Kahatt, C., Zeaiter, A., Paz-Ares, L.

Get full text